By Fineline Cube 
UK major AstraZeneca (AZ, NASDAQ: AZN) this week reportedly unveiled a new organizational restructuring plan, according to local media. The changes include the establishment of a dedicated gastrointestinal oncology business unit under the oncology division. This new unit will focus on developing innovative drugs and combination therapies for various gastrointestinal cancers, including biliary tract cancer, liver cancer, esophageal cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Leadership Appointments
Dr. Wang Jun, currently head of central marketing in the lung cancer business unit, has been appointed as assistant vice president of AstraZeneca China and head of the gastrointestinal oncology business unit. Reporting to Dr. Wang Jun will be Wang Haijun, executive director of gastrointestinal oncology marketing, and Wang Huili, national sales director of gastrointestinal oncology.
Early Pipeline Business Unit
The company will also create an early pipeline business unit. This unit will enhance the management of AstraZeneca’s oncology pipeline in China, strengthen collaboration with global R&D teams, and ensure the successful launch of new products and indications. AstraZeneca China will conduct internal and external recruitment for the position of vice president and head of the early pipeline business unit. The current oncology product pipeline & strategy team will report to the newly appointed leader.-Fineline Info & Tech